Novartis is just months away from filing for ... and multiple sclerosis (MS), and in phase 2 for hidradenitis suppurativa (HS) and food allergy. Analysts have suggested that approval in CSU ...

When Vas Narasimhan started as the new CEO of the Swiss drug giant Novartis, he began refocusing the company on a key business area: prescription medicines. Until recently, alongside top-selling ...

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero Prostate Cancer’s Blitz the Barriers, a project designed to address ...

Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income, supporting Novartis' EPS growth trajectory. The acquisition of Anthos Therapeutics and ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on NVS: Novartis NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024 ... driven by new launches in HS and IV formulations. The brand remains a leader in the IL-17 category across key markets.

This article was coproduced with Kody Kester. Since last October, Novartis' shares have lagged the S&P 500 index. The pharmaceutical company's pipeline remains robust, which could translate into ...

ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...

Novartis has a 12 month low of $92.35 and a 12 month high of $120.92. Get Novartis alerts: Novartis (NYSE:NVS – Get Free Report) last announced its quarterly earnings results on Friday ...